866-997-4948(US-Canada Toll Free)

Pemphigus Vulgaris - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Nov 2016

Category :

Pharmaceutical

No. of Pages : 55 Pages

Pemphigus Vulgaris - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pemphigus Vulgaris Pipeline Review, H2 2016, provides an overview of the Pemphigus Vulgaris (Immunology) pipeline landscape.

Pemphigus vulgaris is a rare autoimmune disease that causes painful blistering on the skin and the mucous membranes. Risk factors include race, gender and age. Symptoms of pemphigus vulgaris include painful blisters that start in the mouth, skin blisters that come and go; the blisters always occur near the surface of the skin and oozing, crusting, or peeling at the blister site.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pemphigus Vulgaris Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Pemphigus Vulgaris (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pemphigus Vulgaris (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Pemphigus Vulgaris and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical, Discovery and Unknown stages are 1, 3, 1, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.Pemphigus Vulgaris.

Pemphigus Vulgaris (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Pemphigus Vulgaris (Immunology).
- The pipeline guide reviews pipeline therapeutics for Pemphigus Vulgaris (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Pemphigus Vulgaris (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Pemphigus Vulgaris (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Pemphigus Vulgaris (Immunology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Pemphigus Vulgaris (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Pemphigus Vulgaris (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Pemphigus Vulgaris Overview 6
Therapeutics Development 7
Pipeline Products for Pemphigus Vulgaris - Overview 7
Pipeline Products for Pemphigus Vulgaris - Comparative Analysis 8
Pemphigus Vulgaris - Therapeutics under Development by Companies 9
Pemphigus Vulgaris - Therapeutics under Investigation by Universities/Institutes 10
Pemphigus Vulgaris - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Unknown Stage Products 14
Pemphigus Vulgaris - Products under Development by Companies 15
Pemphigus Vulgaris - Products under Investigation by Universities/Institutes 16
Pemphigus Vulgaris - Companies Involved in Therapeutics Development 17
Almirall, S.A. 17
Biogen Inc 18
HanAll Biopharma Co., Ltd. 19
Immunomedics, Inc. 20
Novartis AG 21
Principia Biopharma Inc. 22
Pemphigus Vulgaris - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Target 24
Assessment by Mechanism of Action 26
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
ADP-31415 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
Cellular Immunotherapy for Pemphigus Vulgaris - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
Cellular Immunotherapy for Pemphigus Vulgaris - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
DPC-006 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
HL-161 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
PRN-1008 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
rituximab - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
VAY-736 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
veltuzumab - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
Pemphigus Vulgaris - Dormant Projects 50
Pemphigus Vulgaris - Discontinued Products 51
Pemphigus Vulgaris - Product Development Milestones 52
Featured News & Press Releases 52
Jan 07, 2016: Principia Biopharma Advances BTK Inhibitor Program in Autoimmune Disease and FGFR Inhibitor Program in Oncology 52
Aug 25, 2015: Genentech Initiates Phase III Trial of Rituxan for Rare, Autoimmune Disease: Pemphigus Vulgaris 52
Appendix 54
Methodology 54
Coverage 54
Secondary Research 54
Primary Research 54
Expert Panel Validation 54
Contact Us 54
Disclaimer 55

List of Tables
Number of Products under Development for Pemphigus Vulgaris, H2 2016 7
Number of Products under Development for Pemphigus Vulgaris - Comparative Analysis, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Number of Products under Investigation by Universities/Institutes, H2 2016 10
Comparative Analysis by Late Stage Development, H2 2016 11
Comparative Analysis by Clinical Stage Development, H2 2016 12
Comparative Analysis by Early Stage Development, H2 2016 13
Comparative Analysis by Unknown Stage Development, H2 2016 14
Products under Development by Companies, H2 2016 15
Products under Investigation by Universities/Institutes, H2 2016 16
Pemphigus Vulgaris - Pipeline by Almirall, S.A., H2 2016 17
Pemphigus Vulgaris - Pipeline by Biogen Inc, H2 2016 18
Pemphigus Vulgaris - Pipeline by HanAll Biopharma Co., Ltd., H2 2016 19
Pemphigus Vulgaris - Pipeline by Immunomedics, Inc., H2 2016 20
Pemphigus Vulgaris - Pipeline by Novartis AG, H2 2016 21
Pemphigus Vulgaris - Pipeline by Principia Biopharma Inc., H2 2016 22
Assessment by Monotherapy Products, H2 2016 23
Number of Products by Stage and Target, H2 2016 25
Number of Products by Stage and Mechanism of Action, H2 2016 27
Number of Products by Stage and Route of Administration, H2 2016 29
Number of Products by Stage and Molecule Type, H2 2016 31
Pemphigus Vulgaris - Dormant Projects, H2 2016 50
Pemphigus Vulgaris - Discontinued Products, H2 2016 51

List of Figures
Number of Products under Development for Pemphigus Vulgaris, H2 2016 7
Number of Products under Development for Pemphigus Vulgaris - Comparative Analysis, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Comparative Analysis by Early Stage Products, H2 2016 13
Assessment by Monotherapy Products, H2 2016 23
Number of Products by Targets, H2 2016 24
Number of Products by Stage and Targets, H2 2016 24
Number of Products by Top 10 Mechanism of Actions, H2 2016 26
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 26
Number of Products by Routes of Administration, H2 2016 28
Number of Products by Stage and Routes of Administration, H2 2016 28
Number of Products by Molecule Types, H2 2016 30
Number of Products by Stage and Molecule Types, H2 2016 30

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *